The cytokine TRAIL (tumor necrosis factor a-related apoptosisinducing ligand) as well as agonistic antibodies that bind to the TRAIL receptors, death receptor 4 (DR4) and DR5, are undergoing preclinical and early clinical evaluation as potential therapeutic agents for a variety of hematological and nonhematological malignancies. Here, we briefly review the normal biological function of TRAIL, the mechanism of cytotoxicity of TRAIL receptor ligands, and their effects on normal myeloid progenitors, myelodysplastic marrow and leukemic cells, including acute myelogenous leukemia (AML) and chronic lymphocytic leukemia (CLL), in vitro. Recent observations suggesting that DR4 is the predominant receptor for the cytotoxic effects of TRAIL in CLL and that histone deacetylase inhibitors synergize with TRAIL in CLL in vitro are described and discussed. Collectively, the reviewed studies not only illustrate the potential therapeutic usefulness of TRAIL and the agonistic antibodies, but also highlight the need for additional preclinical evaluation of these agents.
Therapy of human leukemia has come a long way in the last 58 years since the gray days of November 1947, when Sidney Farber and his colleagues administered aminopterin to children with acute lymphoblastic leukemia (ALL) and achieved the first remarkable, albeit all-too-brief, clinical remissions. 1, 2 Today, most children with ALL are cured. 3 The outlook for adults with leukemia, however, remains less promising. Despite increases in the complete response (CR) rate, adults with ALL almost universally relapse after conventional chemotherapy. 4, 5 For patients with acute myelogenous leukemia (AML), the 5-year survival rate has hovered at 20-30% since the 1970s 6 , and those with AML arising out of myelodysplastic syndrome (MDS) or a myeloproliferative disorder do even worse. 7 While molecular remissions have recently been described in chronic lymphocytic leukemia (CLL) with purine analog and alkylating agent combination therapy (see below), the impact of these molecular remissions on long-term survival remains to be established. Even with chronic myelogenous leukemia (CML), a disease in which imatinib 8 and additional molecularly targeted agents [9] [10] [11] have been spectacularly successful, the development of drug resistance remains a looming problem. 9, 12, 13 Thus, there remains a need for new, rationally designed, minimally toxic, unequivocally effective therapies for all of these leukemias.
In this context, a recent article in Cell Death and Differentiation might be of potential interest, especially for investigators involved in preclinical work and clinical trials focusing on apoptosis-inducing agents and chromatin-modifying drugs. In that study, MacFarlane et al 14 not only expand on their previous work demonstrating that the cytotoxicity of tumor necrosis factor a-related apoptosis-inducing ligand (TRAIL, also known as Apo2L) in CLL cells is enhanced by simultaneous treatment with histone deacetylase (HDAC) inhibitors, but also report that TRAIL-induced death of CLL cells predominantly reflects engagement of death receptor 4 (DR4, also known as TRAIL-R1) rather than death receptor 5 (DR5, also known as TRAIL-R2, TRICK2, or KILLER). In order to place these findings in context, we briefly review the biology of DR-mediated apoptosis and previous preclinical studies of TRAIL in MDS and leukemia before discussing the new findings of MacFarlane and co-workers in more detail.
Death receptor-mediated cell death
Members of the tumor necrosis factor a (TNFa) superfamily are type I membrane-bound cell surface polypeptides that signal to target cells upon cell-cell contact or after protease-mediated release to the extracellular space. 15 Many members of this family, including B-lymphocyte stimulator (BLyS), promote survival and proliferation in target cells. On the other hand, four members of this family -Fas ligand (FasL), TNFa, TL1A (a recently discovered TNF-like ligand), and TRAIL -stand out because of their ability to induce cell death under certain circumstances. 16, 17 In most cases, binding of TNFa superfamily members to their receptors results in activation of nuclear factor-kB (NF-kB), a transcription factor that upregulates expression of a number of survival-promoting polypeptides, 18 including the X-chromosome-linked inhibitor of apoptosis (XIAP) protein and cellular FLICE-like inhibitory protein (c-FLIP), which are described below. While activation of survival pathways is a common response to TNFa family ligands, the receptors for FasL, TNFa, TL1A, and TRAIL are unique among members of the TNFa receptor (TNFR) family because their ligation sometimes leads to cell death instead of survival.
Studies performed over the past decade have outlined the pathway by which this death signaling occurs (Figure 1) . 15, 17, [19] [20] [21] [22] With the exception of TNFR2, the larger (p75) of the two TNFa receptors, each of the receptors for a cytotoxic TNFa family ligand contains a so-called death domain near its cytoplasmic terminus. In the case of Fas (CD95) as well as the TRAIL receptors DR4 and DR5, binding of ligand to the extracellular domain of the receptor enhances the affinity of the intracellular death domain for the cytoplasmic adaptor protein FADD (Fas-associated protein with death domain). Once bound to the receptor, FADD in turn recruits procaspase 8, a monomeric cytoplasmic zymogen. 23 In a two-step process that is postulated to involve dimerization-induced conformational changes that impart enzymatic activity to the caspase 8 zymogen followed by cleavage of each caspase 8 dimer by a neighboring dimer, 24 the FADD/procaspase 8 binding results in caspase 8 activation. Procaspase 10 is less intensively studied but appears to be activated similarly. 25, 26 Fully mature, enzymatically active caspases 8 and 10 are released to the cytoplasm, where they then cleave a handful of substrates, including procaspase 3 and the proapoptotic Bcl-2 family member Bid (BH3 interacting death domain agonist), which is described below. Recent studies have shown that signaling induced by TNFa through the smaller of its receptors (TNFR1) also induces activation of procaspases 8 and 10, although current understanding suggests that a different adapter molecule (TRADD, TNFR1-associated death domain protein) is initially recruited to the TNFR1 death domain. 27 In addition, it appears that TNFR1/TRADD complexes are formed after TNFR1 has been internalized and dissociated from TNFa rather than at the cell surface. 28 Once formed, these TRADD-containing complexes then recruit FADD and procaspase 8.
While the broad outlines of this pathway are well established, there are several gaps in our current knowledge. First, it is not clear, at the molecular level, how binding of ligand to the extracellular domain of a DR promotes interaction of the intracellular domain of the receptor with FADD or TRADD. Second, the recent demonstration that a succession of complexes, some of which activate NF-kB and others which activate caspase 8, form sequentially at the intracellular domain of TNFR1 28 raises the question of whether different complexes separated in time and space are also formed at the cytoplasmic domains of the other DRs. Third, the process of caspase 8 maturation is incompletely understood. Even though in vitro studies have demonstrated that dimerization of caspase 8 zymogens results in initial acquisition of activity, how (or even whether) binding to FADD results in procaspase 8 dimerization in situ is unsettled. 29 Fourth, the role of c-FLIP, a caspase 8/10 homolog that lacks a catalytic cysteine residue, in this process remains controversial. While some studies suggest that high concentrations of c-FLIP can inhibit caspase 8 activation, 30 others suggest that c-FLIP can substitute for one procaspase 8 monomer and promote dimerization-induced caspase 8 activation. [31] [32] [33] Fifth, it is unclear whether caspases 8 and 10 play equivalent roles. Some studies suggest that this might be the case, but at least one study has suggested that caspase 10 cannot substitute for caspase 8 during DR-induced cell death. 34 Finally, other factors governing the activation of this pathway require further investigation. For instance, in the case of TNFR1, a cytoplasmic polypeptide termed 'silencer of death domains' has been reported to bind the receptor and regulate its oligomerization. 35 Whether other DRs are subject to similar regulation is unknown. More recent studies have demonstrated that activation of protein kinase C isoforms by phorbol esters inhibits signaling by Fas, 36,37 TNFR1, 37 and TRAIL receptors, 37, 38 but the molecular basis for this regulation has also remained unclear.
Type I and type II cells
Once caspase 8 and/or 10 are activated, signaling through two different proteolytic pathways can lead to subsequent cellular disassembly. In the so-called 'type I' cells ( Figure 1 ), caspase 8 and/or 10 act on constitutively expressed procaspase 3 dimers to induce their activation. 39 Activated caspase 3 then digests hundreds of cellular polypeptides that normally maintain the structural and biochemical integrity of cells, 40, 41 including ICAD (inhibitor of caspase-activated deoxyribonuclease), which releases its partner CAD in an active form that digests the nuclear DNA. 42 Collectively, these cleavages lead to various morphological and biochemical changes that are recognized as hallmarks of apoptosis. Death receptor signaling in type I cells. As indicated in the text, ligand binding to the extracellular domain of the receptor Fas leads to FADD recruitment followed by caspase 8 activation mediated by the intracellular domain of the receptor. Caspase 8 then cleaves a small number of polypeptides, including procaspase 3, which digests a large number of substrates, including the inhibitor of caspase-activated DNase (ICAD), to generate biochemical alterations that disrupt cellular homeostasis and result in the phenotypic changes recognized as apoptosis. TRAIL signaling through DR4 and/or DR5 is thought to activate the same signaling as Fas.
In the so-called 'type II' cells, the pathway leading from DR ligation to cellular disassembly is less direct (Figure 2 ). The amount of caspase 3 initially activated by caspases 8 and/or 10 is insufficient to trigger the apoptotic process, 39 possibly because of the effects of the caspase inhibitor XIAP. 43, 44 Consequently, apoptotic signaling in these cells proceeds through caspase 8-mediated cleavage of Bid, 45 a cytosolic proapoptotic Bcl-2 family member that shares sequence homology with Bcl-2 in the 9-amino-acid BH3 domain. 46, 47 Cleaved Bid then interacts with the cytosolic Bcl-2 family member Bax (Bcl-2-associated X protein) and/or the loosely bound mitochondrial homolog Bak (Bcl-2 antagonist/killer) to induce their oligomerization and insertion into the outer mitochondrial membrane, where they contribute to disruption of the barrier between the mitochondrial intermembrane space and the cytoplasm. [48] [49] [50] One of the polypeptides that is released from mitochondria is cytochrome c, which induces ATP-or dATP-dependent assembly of a cytoplasmic complex termed an 'apoptosome' that consists of procaspase 9 bound to a constitutively expressed cytosolic scaffolding protein called apoptotic protease activating factor 1 (Apaf-1). 51 As is the case for FADD/procaspase 8 interactions, Apaf-1/procaspase 9 interactions cause oligomerization and activation of procaspase 9, 52,53 which can then proteolytically activate additional caspase 3. These effects are further amplified by release of additional polypeptides from the mitochondrial intermembrane space, including a polypeptide known as Smac/DIABLO (second mitochondrial activator of caspases/direct IAP binding protein with low pI), which binds to and neutralizes the inhibitory effects of XIAP on caspases 3 and 9.
51,54
Physiological and potential therapeutic role of DR ligands
In view of the ability of DR ligands to induce death in susceptible cell types, there has been considerable interest in the physiological roles and therapeutic potential of these cytokines, both for immunologically mediated conditions and neoplasia. TNFa is ordinarily involved in facilitating dendritic cell maturation, in sustaining the immune response, and in the defense against intracellular pathogens.
17 TNFa/TNFR interactions have been successfully targeted by the anti-TNFa monoclonal antibodies infliximab and adalimumab, which bind and neutralize circulating TNFa, and by etanercept, a soluble TNFR analog that competitively prevents binding of TNFa to its cell surface receptors. These agents are currently administered for a Figure 2 Death receptor signaling in type II cells. As indicated in the text, high levels of XIAP, which is an inhibitor of caspases 3, 7, and 9, are thought to initially prevent caspase 3 action downstream of caspase 8 in type II cells. In these cells, caspase 8-mediated cleavage of the cytoplasmic BH3-only polypeptide Bid generates a truncated C-terminal fragment that induces a presumed conformational change in Bax and/or Bak, which then insert into the outer mitochondrial membrane and participate in the release of a number of polypeptides that are normally localized to the mitochondrial intermembrane space. Among the released polypeptides, cytochrome c induces a conformation change in Apaf-1, leading to the formation of an active high molecular weight Apaf-1/procaspase 9 complex termed the 'apoptosome,' and Smac antagonizes XIAP, thereby facilitating the digestion of various substrates by caspases 9 and 3 to generate the same apoptotic biochemical changes observed in type I cells. TRAIL as well as Fas utilizes this signaling pathway in cells with high XIAP levels.
variety of autoimmune disorders, including rheumatoid arthritis and inflammatory bowel disease. In view of the cytotoxicity observed when high concentrations of TNFa are administered to cancer cells, particularly under conditions where NF-kBinduced protein synthesis is inhibited, 18, 55 clinical trials of TNFa as a systemically administered antineoplastic agent were performed. However, these were quickly abandoned because of sepsis-like side effects. 56 On the other hand, regional administration of TNFa is much better tolerated, and this agent is approved in Europe for the treatment of soft tissue sarcoma by isolated limb perfusion. 57 FasL, the second DR ligand identified, is utilized by cytotoxic lymphocytes (along with perforin and granzymes) to kill their targets, which include neoplastic cells. 20, 58, 59 Since agonistic anti-Fas antibodies are extremely hepatotoxic, 60, 61 clinical development of these antibodies and FasL as possible antineoplastic agents was not attempted. 62 TRAIL has received the most attention as a potential therapeutic death ligand for cancer. [63] [64] [65] This cytokine, which is expressed by natural killer (NK) cells, monocytes, T cells, and neutrophils in response to interferons, 21, 66 appears to be a critical part of the NK cell arsenal against cancers. 21, [66] [67] [68] Consistent with this proposed physiological role, TRAIL is selectively cytotoxic to a wide variety of human tumor cell lines in vitro and when grown as xenografts. [69] [70] [71] An earlier report that TRAIL is toxic to human hepatocytes in tissue culture 72 has not been validated. 73 Likewise, agonistic anti-DR5 antibody kills neoplastic cells in vitro and in vivo, apparently without effects on normal human hepatocytes. 74 Based on these promising preclinical observations, TRAIL from Genentech as well as agonistic anti-DR4 and anti-DR5 antibodies from Human Genome Sciences have recently entered clinical trials.
Molecular determinants of TRAIL sensitivity
In anticipation of these trials, a number of preclinical studies have examined factors that affect sensitivity to TRAIL receptor ligands. TRAIL sensitivity is now known to be regulated at several different steps along the pathway outlined in Figures 1  and 2 . 75, 76 At the cell surface, TRAIL binding reflects a competition between bonafide TRAIL receptors (DR4 and DR5) and so-called 'decoy receptors' (DcR1 and DcR2 and possibly others such as osteoprotegerin), that is, receptor homologs that can bind ligand but cannot signal to FADD. 15, [77] [78] [79] As a result of the number and diversity of these receptors, TRAIL sensitivity is not a simple function of pretreatment DR4 and DR5 expression. [80] [81] [82] Moreover, the balance among these receptors is dynamic rather than static. 83 For example, DR5, which has previously been identified as the more prominent receptor involved in TRAILinduced killing of tumor cells, 84, 85 is upregulated in a p53-dependent manner after DNA damage, [86] [87] [88] providing at least a partial explanation for the ability of DNA-damaging anticancer drugs to synergize with TRAIL in vitro and in vivo. 69, 71, [87] [88] [89] There are other levels of regulation as well. As noted above, the recruitment of FADD by ligated death receptors 37, 38 and the recruitment/activation of caspase 8 by FADD [30] [31] [32] [33] appear to be regulated processes. Finally, the ability of activated caspase 8 to directly trigger apoptosis is regulated, at least in part, by XIAP action. 43, 90 In type II cells, cleavage of Bid to activate the mitochondrial apoptosis pathway plays a critical role in TRAIL signaling, as indicated by studies showing that Bax deletion confers TRAIL resistance in colon cancer cells. 89 Likewise, overexpression of Bcl-2, Bcl-x L or Mcl-1 modulates sensitivity of type II cells to death ligands. 39, 43, [91] [92] [93] [94] [95] Effects of TRAIL on myeloid progenitors from normal marrow, MDS and acute leukemia
In anticipation of possible clinical studies of TRAIL receptor ligands, the role of TRAIL in normal marrow and in hematological disorders has also been previously investigated. Messages encoding DR4 and DR5, as well as TRAIL itself, have been detected in normal myeloid progenitors by RT-PCR. 96, 97 Despite the expression of TRAIL receptors, exogenous TRAIL has little effect on myeloid progenitors from normal marrow, [96] [97] [98] again reinforcing the complexity of signaling through this pathway.
In view of the increased apoptosis observed in MDS marrows, there has been considerable interest in determining whether abnormal DR-mediated signaling plays a role in MDS. Early studies suggested a contribution of elevated TNFa expression to MDS-associated apoptosis, 99 but more recent studies have focused on the potential roles of FasL and TRAIL. In support of the conclusion that FasL contributes to the increased apoptosis in MDS, Claessens et al 100 utilized a two-step in vitro culture system to enrich for cytogenetically abnormal erythroid progenitors and demonstrated overexpression of Fas and FasL but not TRAIL or TNFa in early-stage MDS erythroid cells. Consistent with these results, these investigators observed that synthetic decoy receptors for TNFa and TRAIL failed to improve the viability of MDS erythroid progenitors. Unfortunately, decoy receptors for FasL were not tested in a similar manner to confirm the proposed role of FasL in MDS-associated apoptosis.
Other data have implicated TRAIL in MDS-associated apoptosis. Deeg and co-workers reported increased expression of TRAIL and its receptors in marrow from patients with both early and late MDS. 96 In samples from early MDS, TRAIL induced depletion of cytogenetically abnormal myeloid progenitor colonies and enhanced growth of normal myeloid progenitors in vitro. 96 In samples from more advanced MDS (RAEB-T and t-AML), TRAIL treatment in vitro caused a statistically significant decrease in the number of abnormal myeloid progenitors. 96, 98 Since the effects of blocking antibodies were not examined in these studies, however, it remains unclear in retrospect whether the effects of exogenous TRAIL implicate endogenous TRAIL in the excess apoptosis that accompanies MDS or instead simply reflect increased TRAIL sensitivity of the abnormal myeloid progenitors that are present in MDS.
To complement and extend these studies, several groups have examined TRAIL action in acute leukemia specimens. Regardless of whether RT-PCR 82 or flow cytometry 101 is utilized, expression of DR4 and DR5 is detectable in the vast majority of AML and ALL specimens. Further analysis revealed that TRAIL induces apoptosis in AML blasts 82, 97 and inhibits the growth of AML blast colonies in methylcellulose in vitro, 98 although it is important to again emphasize the lack of clear correlation between TRAIL receptor expression and TRAIL sensitivity in these studies.
Preclinical studies of TRAIL in CLL
In the context of these prior studies in MDS and acute leukemia, several groups have also performed preclinical studies of TRAIL in CLL. Two reasons are typically put forward for considering DR ligands in this disorder. First, CLL has a high frequency of Bcl-2 overexpression, 102 which might inhibit the ability of anticancer drugs to induce apoptosis, whereas death ligands could potentially bypass this mechanism in type I cells (Figure 1) . Second, CLL is often considered a resistant disease that desperately needs new therapies. In light of current understanding, both of these arguments are open to debate. As indicated in Figure 2 , death ligand-induced apoptosis relies on the mitochondrial pathway for amplification in a wide variety of cell types. Thus, it is important to establish whether CLL cells are type I or type II cells before assuming that a death ligand such as TRAIL will overcome Bcl-2-mediated resistance. Moreover, the concept that CLL is a therapy-resistant disease requires reevaluation in view of recent clinical trial data. Leaving aside for the moment the substantial proportion of older CLL patients with indolent disease who never require therapy, newer combination regimens such as fludarabine þ cyclophosphamide þ rituximab have CR rates of 70% (including molecular remissions) in newly diagnosed CLL, with relapse-free survival estimated to be 69% at 4 years. 103 Even in relapsed/refractory CLL, this regimen has a CR rate of 25% and an overall response rate of 73%. 104 Combinations substituting pentostatin for fludarabine might have similar or greater efficacy with less toxicity. 105 This is not meant in any way to minimize the fact that certain subsets of patients, including those whose cells express ZAP70 and/or CD38, contain unmutated V H genes, or exhibit a short lymphocyte doubling time, do particularly poorly with conventional therapy, 106 but simply to indicate that the bar for an effective new CLL therapy will now be extremely high, perhaps even higher than it would be for AML or adult ALL.
All of this background brings us to a series of studies examining the effects of TRAIL on CLL cells in vitro. 88, 107, 108 There was initially hope that treatment of CLL cells with TRAIL might by itself induce apoptosis. Previous studies, however, not only demonstrated that CLL cells are resistant to the induction of apoptosis by TRAIL, 88, 107 but also suggested that recruitment of FADD and cleavage of caspase 8 is low in CLL isolates compared to the Jurkat T-cell leukemia line. 107 In a subsequent study, MacFarlane and co-workers also showed that the HDAC inhibitors depsipeptide and trichostatin A, two examples of a promising new class of anticancer agents undergoing extensive preclinical and clinical investigation, [109] [110] [111] [112] are unable to induce apoptosis in CLL cells by themselves, but nonetheless sensitize CLL cells to TRAIL. 108 In the recent Cell Death and Differentiation paper that prompted this mini-review, MacFarlane et al 14 extend these earlier studies in two interesting and potentially important ways. First, they demonstrate that valproic acid, an agent that inhibits HDACs in tissue culture, [113] [114] [115] mimics depsipeptide in its ability to sensitize CLL cells to some preparations of TRAIL. Second, they show that agonistic anti-DR4 antibody also induces apoptosis in CLL cells in the presence of depsipeptide or valproic acid, whereas agonistic anti-DR5 antibody does not, leading MacFarlane et al to conclude that DR4 is the predominant receptor activated by TRAIL in CLL cells. 14 
Some answers, many questions
Like many good scientific studies, these observations of MacFarlane et al not only answer several questions, but also raise many more:
First, it is unclear whether the reliance on DR4 rather than DR5 is unique to CLL or is more generally seen in hematological and nonhematological malignancies. It is possible that further investigation will overturn the current belief that DR5 is the more important receptor for TRAIL-induced killing of cancer cells. 74, 84, 85 Better understanding of this issue would appear to be critical for identifying neoplasms in which to test the agonistic anti-TRAIL receptor antibodies and TRAIL itself. For example, testing anti-DR5 antibodies in an acute leukemia trial would seem futile if the majority of blasts are sensitive only to DR4-mediated signaling.
Second, it is unclear how HDAC inhibitors are facilitating TRAIL-induced apoptosis in CLL cells. Recent studies have demonstrated that HDAC inhibitors can induce TRAIL expression in AML blasts 116 and enhance TRAIL receptor expression in a variety of leukemia and carcinoma cells. [117] [118] [119] To elucidate which (if either) of these effects is responsible for the observations reported by McFarlane et al in CLL cells will require measurement of TRAIL receptor levels, analysis of FADD and caspase 8 recruitment to ligated receptors, and assessment of other steps in the TRAIL-induced apoptotic pathway (eg, effects on c-FLIP, XIAP, and Bcl-2 family members) in clinical CLL specimens.
Third, it is unclear whether sensitization to TRAIL can be observed at clinically achievable valproic acid concentrations. Although MacFarlane et al examined the effects of 2 mM valproic acid, a concentration suggested by prior studies in vitro, 113, 114 it might be important to note that therapeutic levels of valproic acid in patients are 0.3-0.6 mM 120, 121 and that this agent is extensively protein bound in vivo, making clinically achievable free concentrations correspondingly lower.
Fourth, even if valproic acid concentrations required to increase TRAIL sensitivity are clinically achievable, it is unclear whether valproic acid-induced TRAIL sensitization in isolated CLL cells can be extrapolated to indicate activity of the combination in vivo. CLL cells typically are in contact with stromal cells in situ, and these cell-cell interactions can affect the regulation of apoptotic pathways. Accordingly, it will be important for subsequent studies to examine effects of the combination in the presence of stromal cells or under other conditions that more accurately reflect the resistance likely to be observed in vivo.
Fifth, it is unclear whether TRAIL will retain its selectivity for neoplastic cells in the presence of HDAC inhibitors. For instance, the effects of HDAC inhibitor/TRAIL combinations on normal human hepatocytes and normal myeloid progenitors have not been reported.
Finally, further comparative studies are required in order to determine whether the agonistic DR4 and DR5 antibodies will prove more efficacious and/or more toxic than recombinant TRAIL in suitable preclinical models and in the clinical setting.
As a result of the need for improved therapies for MDS and the acute leukemias as well as certain subsets of CLL patients, studies that address these questions are likely to have important implications for the future clinical development of TRAIL receptor ligands in a wide range of hematological malignancies. Results of these studies are awaited with interest.
